|
| n (%) | QTc prolongation (%)a | Odds ratio (95% CI) | p value |
| Gender |
|
|
|
|
| Female | 670 (46.6) | 89 (13.3) | 1.83 (1.28 - 2.56) | 0.001 |
| Male | 767 (53.4) | 59 (7.7) | 1.00 |
|
| Age (years) |
|
|
|
|
| <65 | 1290 (89.8) | 131 (10.2) | 1.06 (0.61 - 1.83) | 0.846 |
| >65 | 147 (10.2) | 17 (11.6) | 1.00 |
|
| CYP 1A2 |
|
|
|
|
| CYP 1A2-mediated drugs | 637 (44.3) | 58 (9.1) | 0.65 (0.44 - 0.97) | 0.033 |
| Non CYP 1A2-mediated drugs | 800 (55.7) | 90 (11.3) | 1.00 |
|
| CYP 2D6 |
|
|
|
|
| CYP 2D6-mediated drugs | 1414 (98.4) | 145 (10.3) | 0.94 (0.27 - 3.33) | 0.925 |
| Non CYP 2D6-mediated drugs | 23 (1.6) | 3 (13.0) | 1.00 |
|
| CYP 3A4 |
|
|
|
|
| CYP 3A4-mediated drugs | 574 (39.9) | 68 (11.8) | 1.56 (1.05 - 2.30) | 0.026 |
| Non CYP 3A4-mediated drugs | 863 (60.1) | 80 (9.3) | 1.00 |
|